此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring (PANXEON)

2026年7月13日 更新者:Alessandro Mannucci、Università Vita-Salute San Raffaele

An Exosome-based and Machine-learning-powered Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology

研究概览

详细说明

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations-including individuals with hereditary or familial pancreatic cancer and those with mucinous pancreatic cystic lesions-but these approaches are invasive, costly, and suboptimal in sensitivity.

The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology, with the hypothesis that combined microRNA profiling can improve molecular risk stratification and potentially anticipate disease progression compared with standard imaging-based surveillance alone. The study population will include adult men and women (≥18 years) at increased risk for PDAC due to familial or hereditary predisposition or mucinous pancreatic cysts, with generally stable health status and existing clinical follow-up; no vulnerable populations are specifically targeted.

No medicinal products or medical devices are administered in this study. The procedure under investigation consists exclusively of laboratory-based measurement of microRNA expression from previously collected plasma samples, using validated exosome isolation and quantification techniques, with no impact on clinical management. Available preliminary and published data demonstrate that combined cell-free and exosomal microRNA signatures can detect early-stage PDAC with high accuracy and show dynamic behavior during disease progression and treatment, supporting their relevance for risk stratification and disease monitoring. Clinical, demographic, and laboratory data will be retrieved.

研究类型

观察性的

注册 (估计的)

600

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • MI
      • Milan、MI、意大利、20132
        • 招聘中
        • IRCCS San Raffaele Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不适用

取样方法

非概率样本

研究人群

Selection of participants will be equitable and non-discriminatory, with no exclusion based on sex, ethnicity, or socioeconomic status. Pediatric populations are excluded due to the rarity of PDAC risk conditions in this group and the absence of relevant stored biospecimens.

描述

Inclusion Criteria:

  • Adult men or women aged ≥18 years at the time of plasma sample collection.
  • Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome
  • Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to the presence of one (or more) mucinous pancreatic cystic lesion(s).
  • Availability of stored plasma samples collected as part of routine clinical care or surveillance and archived in the institutional biobank.
  • Availability of relevant clinical and demographic data in institutional medical records sufficient to address study objectives.
  • Prior provision of informed consent for biobanking and research use of biological samples and data

Exclusion Criteria:

  • Absence or insufficient quality/quantity of stored plasma samples for laboratory analysis.
  • Lack of clinical data required for cohort classification and/or outcome assessment.
  • History of pancreatic surgery or interventional procedures prior to plasma sample collection.
  • Concurrent active malignancy at the time of sample collection, other than non-melanoma skin cancer.
  • Samples collected outside routine clinical care or not compliant with institutional biobanking and data protection policies.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Familial pancreatic cancer (FPC)

This term refers to individuals who are at a higher risk of developing pancreatic cancer based on their family history. There are two main risk categories:

  • 2 relatives with pancreatic cancer, who are first-degree relative of each other, and at least one should be a first degree relative of the individual for whom surveillance is being considered
  • 3 or more relatives with pancreatic cancer, regardless of the degree
A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples
Hereditary pancreatic cancer (HPC)

This terms encompasses all individuals who are at an increased risk of developing pancreatic cancer based on the presence of a pathogenic (or likely pathogenic) germline variant. More specifically:

  • All individuals with a pathogenic (or likely pathogenic) germline variant in Serine/Threonine Kinase 11 (STK11), cyclin-dependent kinase inhibitor 2A (CDKN2A), Ataxia-Telangiectasia Mutated (ATM), and Breast cancer type 2 (BRCA2) genes, regardless of their family history of pancreatic cancer
  • Individuals who have both (i) a pathogenic (or likely pathogenic) germline variant in Breast cancer type 1 (BRCA1), Partner and Localizer of BRCA2 (PALB2), Mutator L Homolog 1 (MLH1), Mutator S Homolog 2 (MSH2), Mutator S Homolog 6 (MSH6), Postmeiotic Segregation 1 Homolog 2 (PMS2), or Epithelial Cell Adhesion Molecule (EPCAM) genes; and (ii) at least one relative diagnosed with pancreatic cancer
A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples
Mucinous Pancreatic Neoplasms (MPN)
This term refers collectively to cystic lesions of the pancreas that confer an increased risk of developing pancreatic cancer. Collectively, this term encompasses both Intraductal Pancreatic Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasias (MCNs)
A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
灵敏度
大体时间:通过学习完成,平均1年
真阳性率:检测结果呈阳性的概率,以个体真正呈阳性为条件
通过学习完成,平均1年

次要结果测量

结果测量
措施说明
大体时间
特异性
大体时间:通过学习完成,平均1年
真阴性率:检测结果呈阴性的概率,以个人真正呈阴性为条件
通过学习完成,平均1年
正确预测(真阳性和真阴性)占病例总数的比例(即准确率)
大体时间:通过学习完成,平均1年
真实性衡量标准:正确预测(真阳性和真阴性)占所检查病例总数的比例
通过学习完成,平均1年

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Alessandro Mannucci, MD、Università Vita-Salute San Raffaele

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月3日

初级完成 (估计的)

2031年12月31日

研究完成 (估计的)

2032年1月30日

研究注册日期

首次提交

2026年7月8日

首先提交符合 QC 标准的

2026年7月13日

首次发布 (实际的)

2026年7月14日

研究记录更新

最后更新发布 (实际的)

2026年7月14日

上次提交的符合 QC 标准的更新

2026年7月13日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

Data collected for the study will be made available to others, including de-identified participant data, at publication, via a signed data access agreement and at the discretion of the investigators' approval of the proposed use of such data

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅